目的 評價小兒智力糖漿聯(lián)合哌甲酯治療注意力缺陷多動障礙的臨床療效及安全性。方法 計算機檢索中國學術期刊全文數據庫（CNKI）、中國生物醫(yī)學文獻數據庫（CBM）、維普中文期刊全文數據庫（VIP）、萬方數據庫、the Cochrane Library、PubMed和Web of Science中英文數據庫，收集各數據庫建庫起至2021年12月26日小兒智力糖漿聯(lián)合哌甲酯治療注意力缺陷多動障礙的臨床隨機對照試驗（RCT）。由兩位研究人員獨立篩選文獻、提取資料，使用RevMan 5.4軟件分析數據。結果 共納入9項RCTs、包括861例患兒。Meta分析結果顯示：小兒智力糖漿聯(lián)合哌甲酯組在多動指數評分[MD=-0.32，95% CI（-0.40，-0.23），P<0.000 01]、沖動行為評分[MD=-0.38，95% CI（-0.48，-0.29），P<0.000 01]、學習行為評分[MD=-0.36，95% CI（-0.43，-0.29），P<0.000 01]、不良反應率[RR=0.64，95% CI（0.46，0.89），P=0.009]方面，與對照組比較，差異均有統(tǒng)計學意義。結論 小兒智力糖漿聯(lián)合哌甲酯治療注意力缺陷多動障礙的療效優(yōu)于單用哌甲酯，且更安全。

Objective To systematically evaluate the clinical efficacy and safety of Xiaoer Zhili Syrup combined with methylphenidate in the treatment of attention-deficit hyperactivity disorder (ADHD). Methods Literature search was conducted across CNKI, CBM, VIP, Wanfang Database, the Cochrane Library, PubMed, and Web of Science, to search for randomized controlled trial (RCT) of Xiaoer Zhili Syrup combined with methylphenidate in the treatment of ADHD. The retrieval time is from the establishment of the database to December 26, 2021. There are two researchers that independently screened the literature, extracted data, and analyzed the risk of bias in the included literature by using RevMan 5.4 software. Results A total of nine RCTs were included for analysis, including 861 children with ADHD. The results of Meta-analysis of Xiaoer Zhili Syrup combined with methylphenidate group compared to control group:hyperactivity index score[MD=-0.32, 95%CI (-0.40, -0.23), P < 0.000 01], impulsive behavior score[MD=-0.38, 95%CI (-0.48, -0.29), P < 0.000 01], learning behavior score[MD=-0.36, 95%CI (-0.43, -0.29), P < 0.000 01], adverse reaction rate[RR=0.64, 95%CI (0.46, 0.89), P=0.009], there are differences statistical significance. Conclusion Xiaoer Zhili Syrup combined with methylphenidate in the treatment of ADHD is more effective than methylphenidate alone and is safer.

R287.5

國家自然科學基金青年科學基金資助項目（82004422）